.AstraZeneca has actually shared a very early take a look at the efficiency of its in-house antibody...
.After declaring a phase 3 launch based on favorable midstage outcomes, iTeos and also GSK are actua...
.The FDA should be much more available as well as joint to unleash a surge in approvals of uncommon ...
.It's an uncommonly active Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutic...
.Atea Pharmaceuticals' antiviral has actually failed yet another COVID-19 trial, but the biotech sti...
.Neurocrine Biosciences' schizophrenia plan pivot has actually stopped working. The biotech was not ...
.Sanofi has actually made a late access to the radioligand gathering, paying out 100 million europea...
.After F2G's initial effort to obtain a brand-new training class of antifungal to market was deraile...
.Moderna has pledged to cut R&D investing through $1.1 billion by 2027. The selection to shrink t...
.Merely 4 months after Sanofi wager $80 million in beforehand cash on Pivot Therapies' losmapimod, t...